Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 2 Clinical characteristics of ALHIV at TASO Mbale and Soroti COEs, included in the study

From: “Swallowing these drugs every day, you get tired”: a mixed-methods study to identify barriers and facilitators to retention and HIV viral load suppression among the adolescents living with HIV in TASO Mbale and TASO Soroti centers of excellence

Variables

Frequency (N = 533)

Proportion (percentage)

Current retention at 12 months

  

 Active

511

95.9

 Died

4

0.8

 Transferred out

8

1.5

 Lost > 28 days

10

1.9

Current viral load suppression

  

 Non-suppressed

134

25.1

 Suppressed

399

74.9

Adherence scores

  

 Good

494

92.7

 Fair

27

5.1

 Poor

12

2.3

Baseline WHO clinical stage

  

 Clinical stage I

50

9.4

 Clinical stage II

438

82.2

 Clinical stage III

32

6.0

 Clinical stage IV

13

2.4

Baseline CD4 count

  

  < 200 copies

66

12.4

  >  = 200 copies

209

39.2

 Not done

258

48.4

Current ART regimen

  

 ABC-3TC-DTG

88

16.5

 AZT-3TC-DTG

29

5.4

 TDF-3TC-DTG

406

76.2

 TDF-3TC-LPV/r

1

0.2

 Other

9

1.7

Current ART line

  

 First line

449

84.2

 Second line

71

13.3

 Third line

13

2.4

Current DSDM approach

  

 CCLAD (community client-led ART Delivery)

25

4.7

 CDDP (Community drug delivery points)

106

19.9

 FBG (facility-based groups)

354

66.4

 FBIM (facility-based individual management)

40

7.5

 FTDR (Fast-track drug refills)

8

1.5

MUAC (Mid-upper arm circumference)

  

 Green

498

93.4

 Yellow

23

4.3

 Red

12

2.3

TB status

  

 No signs and symptoms

498

93.4

 Presumptive

28

5.3

 TB diagnosed

7

1.3

OVC (orphaned and vulnerable children) status

  

 Ever enrolled

323

60.6

 Never enrolled

210

39.4

Benefited from OVC services (N = 323)

  

 No

62

19.2

 Yes

261

80.8

MMD (multi-month dispensing)

  

  < 3_months

59

11.1

 3 to 5 months

273

51.2

 More than 5 months

201

37.7

Disclosure status

  

 Yes

522

97.9

 No

11

2.1